APA (7th ed.) Citation

Raynes, G., Stares, M., Low, S., Haron, D., Sarwar, H., Abhi, D., . . . MacKean, M. (2023). Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer. Cancers, 15(23), 5502. https://doi.org/10.3390/cancers15235502

Chicago Style (17th ed.) Citation

Raynes, George, et al. "Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer." Cancers 15, no. 23 (2023): 5502. https://doi.org/10.3390/cancers15235502.

MLA (9th ed.) Citation

Raynes, George, et al. "Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer." Cancers, vol. 15, no. 23, 2023, p. 5502, https://doi.org/10.3390/cancers15235502.